CTSS and diffuse large B-cell lymphoma: Not only that, a nanocarrier-mediated drug delivery system with targeted delivery and release capabilities to promote antitumor immunity is being developed.[51] In addition, inhibitory monoclonal antibodies targeting human CTSS have been designed and produced.[47] Although no consensus has been achieved on the mechanisms underlying the causal effect of CTSS and DLBCL, undoubtedly, the findings of this study provide a fresh perspective on the treatment of patients with DLBCL.